185 related articles for article (PubMed ID: 31121355)
1. The Ca
Cao C; Oswald AB; Fabella BA; Ren Y; Rodriguiz R; Trainor G; Greenblatt MB; Hilton MJ; Pitt GS
Bone; 2019 Aug; 125():160-168. PubMed ID: 31121355
[TBL] [Abstract][Full Text] [Related]
2. The effect of sex hormones on bone metabolism of the otic capsule--an overview.
Horner KC
Hear Res; 2009 Jun; 252(1-2):56-60. PubMed ID: 19121641
[TBL] [Abstract][Full Text] [Related]
3. Differential gene expression in the otic capsule and the middle ear--an annotation of bone-related signaling genes.
Nielsen MC; Martin-Bertelsen T; Friis M; Winther O; Friis-Hansen L; Rye-Jørgensen N; Bloch S; Sørensen MS
Otol Neurotol; 2015 Apr; 36(4):727-32. PubMed ID: 25406873
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss.
Zehnder AF; Kristiansen AG; Adams JC; Kujawa SG; Merchant SN; McKenna MJ
Laryngoscope; 2006 Feb; 116(2):201-6. PubMed ID: 16467704
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin in the inner ear may inhibit bone remodeling in the otic capsule.
Zehnder AF; Kristiansen AG; Adams JC; Merchant SN; McKenna MJ
Laryngoscope; 2005 Jan; 115(1):172-7. PubMed ID: 15630389
[TBL] [Abstract][Full Text] [Related]
6. Resorption of auditory ossicles and hearing loss in mice lacking osteoprotegerin.
Kanzaki S; Ito M; Takada Y; Ogawa K; Matsuo K
Bone; 2006 Aug; 39(2):414-9. PubMed ID: 16564235
[TBL] [Abstract][Full Text] [Related]
7. Increased Ca2+ signaling through CaV1.2 promotes bone formation and prevents estrogen deficiency-induced bone loss.
Cao C; Ren Y; Barnett AS; Mirando AJ; Rouse D; Mun SH; Park-Min KH; McNulty AL; Guilak F; Karner CM; Hilton MJ; Pitt GS
JCI Insight; 2017 Nov; 2(22):. PubMed ID: 29202453
[TBL] [Abstract][Full Text] [Related]
8. On the biology of the bony otic capsule and the pathogenesis of otosclerosis.
Bloch SL
Dan Med J; 2012 Oct; 59(10):B4524. PubMed ID: 23158898
[TBL] [Abstract][Full Text] [Related]
9. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin.
Kanzaki S; Takada Y; Ogawa K; Matsuo K
J Bone Miner Res; 2009 Jan; 24(1):43-9. PubMed ID: 18715136
[TBL] [Abstract][Full Text] [Related]
11. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
12. Thrombin receptor deficiency leads to a high bone mass phenotype by decreasing the RANKL/OPG ratio.
Tudpor K; van der Eerden BC; Jongwattanapisan P; Roelofs JJ; van Leeuwen JP; Bindels RJ; Hoenderop JG
Bone; 2015 Mar; 72():14-22. PubMed ID: 25460576
[TBL] [Abstract][Full Text] [Related]
13. Postnatal expression and possible function of RANK and RANKL in the murine inner ear.
Kao SY; Katsumi S; Han D; Bizaki-Vallaskangas AJ; Vasilijic S; Landegger LD; Kristiansen AG; McKenna MJ; Stankovic KM
Bone; 2021 Apr; 145():115837. PubMed ID: 33385614
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel.
Bergh JJ; Xu Y; Farach-Carson MC
Endocrinology; 2004 Jan; 145(1):426-36. PubMed ID: 14525906
[TBL] [Abstract][Full Text] [Related]
15. Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.
Li M; Xu D
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17187-17194. PubMed ID: 32636266
[TBL] [Abstract][Full Text] [Related]
16. Effects of dietary calcium to available phosphorus ratios on bone metabolism and osteoclast activity of the OPG /RANK/RANKL signalling pathway in piglets.
Zhao L; Li M; Sun H
J Anim Physiol Anim Nutr (Berl); 2019 Jul; 103(4):1224-1232. PubMed ID: 31062421
[TBL] [Abstract][Full Text] [Related]
17. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
[TBL] [Abstract][Full Text] [Related]
18. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
[TBL] [Abstract][Full Text] [Related]
19. Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
